MET signaling is widely recognized to be an escape pathway to EGFR–TKIs, for which reason there is great interest in combining anti-MET with anti-EGFR therapies in EGFR-mutated NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.